| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NRD3000 |
| P698 | PubMed publication ID | 20339370 |
| P2093 | author name string | Clive N Svendsen | |
| Allison D Ebert | |||
| P2860 | cites work | Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation | Q24297619 |
| Disease-specific induced pluripotent stem cells | Q24641981 | ||
| Virus-free induction of pluripotency and subsequent excision of reprogramming factors | Q24644686 | ||
| Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins | Q24653753 | ||
| Integrative genomic and functional analyses reveal neuronal subtype differentiation bias in human embryonic stem cell lines | Q26269943 | ||
| Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes | Q27350032 | ||
| Induced pluripotent stem cell lines derived from human somatic cells | Q27860597 | ||
| Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors | Q27860937 | ||
| Induction of pluripotent stem cells from adult human fibroblasts by defined factors | Q27860967 | ||
| Embryonic stem cell lines derived from human blastocysts | Q27861010 | ||
| Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis | Q28131805 | ||
| Asymmetric and symmetric stem-cell divisions in development and cancer | Q28249478 | ||
| Reprogramming of human somatic cells to pluripotency with defined factors | Q28262710 | ||
| Design, power, and interpretation of studies in the standard murine model of ALS | Q28268686 | ||
| Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. | Q55032889 | ||
| Japan fast-tracks stem-cell patent | Q81985303 | ||
| Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors | Q28749672 | ||
| Identification and characterization of a spinal muscular atrophy-determining gene | Q29547495 | ||
| Human induced pluripotent stem cells free of vector and transgene sequences | Q29547624 | ||
| Induced pluripotent stem cells from a spinal muscular atrophy patient | Q29614340 | ||
| Generation of mouse induced pluripotent stem cells without viral vectors | Q29614342 | ||
| Induced pluripotent stem cells generated without viral integration | Q29614343 | ||
| Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons | Q29616199 | ||
| Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome | Q29616636 | ||
| A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy | Q29617367 | ||
| Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development | Q29617978 | ||
| Generation of induced pluripotent stem cells using recombinant proteins | Q29619162 | ||
| Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin | Q29619238 | ||
| piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells | Q29619409 | ||
| Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. | Q30489278 | ||
| High-throughput screening assay for the identification of compounds regulating self-renewal and differentiation in human embryonic stem cells | Q33340187 | ||
| Genes associated with Parkinson syndrome | Q33346009 | ||
| Neuronal target genes of the neuron-restrictive silencer factor in neurospheres derived from fetuses with Down's syndrome: a gene expression study | Q34112868 | ||
| The survival motor neuron protein in spinal muscular atrophy | Q34435656 | ||
| Guidelines and techniques for the generation of induced pluripotent stem cells | Q34890821 | ||
| A small molecule primes embryonic stem cells for differentiation | Q34980024 | ||
| Pharmaceutical applications of embryonic stem cells | Q36313790 | ||
| Markers and methods for cell sorting of human embryonic stem cell-derived neural cell populations | Q36453736 | ||
| Translating preclinical insights into effective human trials in ALS. | Q36483369 | ||
| Identification of small molecules from human embryonic stem cells using metabolomics | Q37016135 | ||
| Preclinical assessment of cardiac toxicity | Q37207456 | ||
| Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4. | Q37211408 | ||
| Human stem cells as a model for cardiac differentiation and disease. | Q37371676 | ||
| Upping the ante: recent advances in direct reprogramming | Q37428696 | ||
| Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. | Q37444336 | ||
| Derivation of midbrain dopamine neurons from human embryonic stem cells | Q37493958 | ||
| Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures | Q39830573 | ||
| Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells | Q39864871 | ||
| Human embryonic stem cells reveal recurrent genomic instability at 20q11.21. | Q39912733 | ||
| Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos | Q39997723 | ||
| A clinical trial of creatine in ALS. | Q40469445 | ||
| Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization | Q40641800 | ||
| Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells | Q40648427 | ||
| Correlation between severity and SMN protein level in spinal muscular atrophy | Q41102726 | ||
| ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis | Q42482097 | ||
| A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group | Q43683334 | ||
| A randomized sequential trial of creatine in amyotrophic lateral sclerosis | Q44383439 | ||
| Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes | Q44970476 | ||
| A systems biology approach to Down syndrome: identification of Notch/Wnt dysregulation in a model of stem cells aging. | Q47870632 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 367-372 | |
| P577 | publication date | 2010-03-26 | |
| P1433 | published in | Nature Reviews Drug Discovery | Q45998 |
| P1476 | title | Human stem cells and drug screening: opportunities and challenges | |
| P478 | volume | 9 |
| Q41463305 | 3D brain Organoids derived from pluripotent stem cells: promising experimental models for brain development and neurodegenerative disorders |
| Q39394802 | A human stem cell model of early Alzheimer's disease pathology in Down syndrome |
| Q48009686 | Activin-A enhances mTOR signaling to promote aberrant chondrogenesis in fibrodysplasia ossificans progressiva |
| Q34519522 | Adapting human pluripotent stem cells to high-throughput and high-content screening |
| Q26996412 | Advances in high-throughput single-cell microtechnologies |
| Q90952585 | Advances in the Differentiation of Retinal Ganglion Cells from Human Pluripotent Stem Cells |
| Q91262886 | Alzheimer's disease mechanisms in peripheral cells: Promises and challenges |
| Q38160459 | Amyotrophic lateral sclerosis: applications of stem cells - an update. |
| Q64240331 | Astrocytes Regulate the Development and Maturation of Retinal Ganglion Cells Derived from Human Pluripotent Stem Cells |
| Q92681184 | Benzothiazole amphiphiles promote RasGRF1-associated dendritic spine formation in human stem cell-derived neurons |
| Q36788083 | Cell surface marker mediated purification of iPS cell intermediates from a reprogrammable mouse model. |
| Q28833671 | Cell type-dependent Erk-Akt pathway crosstalk regulates the proliferation of fetal neural progenitor cells |
| Q37274325 | Comparative neurotoxicity screening in human iPSC-derived neural stem cells, neurons and astrocytes |
| Q89174640 | Development of a Three-Dimensional Bioengineering Technology to Generate Lung Tissue for Personalized Disease Modeling |
| Q37004251 | Drug combination therapy increases successful drug repositioning |
| Q64046774 | Drug discovery and development for rare genetic disorders |
| Q27024122 | Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease |
| Q96126759 | Drug response analysis for scaffold-free cardiac constructs fabricated using bio-3D printer |
| Q33565675 | Embryonic stem cell application in drug discovery |
| Q37833506 | Endothelial Cell Vascular Smooth Muscle Cell Co-Culture Assay For High Throughput Screening Assays For Discovery of Anti-Angiogenesis Agents and Other Therapeutic Molecules |
| Q98615078 | Establishment of drug screening in human embryonic stem cells based on a high-content screening system |
| Q37998022 | Generation and applications of human pluripotent stem cells induced into neural lineages and neural tissues |
| Q39410169 | High content screening in neurodegenerative diseases |
| Q36808557 | High-Throughput Phenotypic Screening of Human Astrocytes to Identify Compounds That Protect Against Oxidative Stress |
| Q39050993 | Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening |
| Q26750393 | Human induced pluripotent stem cells for monogenic disease modelling and therapy |
| Q30395748 | Human pluripotent stem cell-derived products: advances towards robust, scalable and cost-effective manufacturing strategies. |
| Q38164195 | In vitro neurogenesis: development and functional implications of iPSC technology |
| Q34499953 | In vivo high-content evaluation of three-dimensional scaffolds biocompatibility. |
| Q36633022 | Induced pluripotent stem cell technology for disease modeling and drug screening with emphasis on lysosomal storage diseases |
| Q38542017 | Induced pluripotent stem cell technology for modelling and therapy of cerebellar ataxia |
| Q37857439 | Induced pluripotent stem cells: a new revolution for clinical neurology? |
| Q34314191 | Inhibition of apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular atrophy |
| Q28543597 | Kuwanon V inhibits proliferation, promotes cell survival and increases neurogenesis of neural stem cells |
| Q33945586 | Microengineered synthetic cellular microenvironment for stem cells |
| Q34519239 | Modeling complex neuropsychiatric disease with induced pluripotent stem cells |
| Q27007542 | Neural differentiation from pluripotent stem cells: The role of natural and synthetic extracellular matrix |
| Q41836711 | Patient-specific pluripotent stem cells in neurological diseases |
| Q36293315 | Peroxisome proliferator-activated receptorβ/δ activation is essential for modulating p-Foxo1/Foxo1 status in functional insulin-positive cell differentiation |
| Q37191636 | Phenotypic assays for β-amyloid in mouse embryonic stem cell-derived neurons |
| Q35936197 | Phenotypic screens as a renewed approach for drug discovery |
| Q34520935 | Present state and future perspectives of using pluripotent stem cells in toxicology research |
| Q35133864 | Promoting effect of 1,25(OH)2 vitamin D3 in osteogenic differentiation from induced pluripotent stem cells to osteocyte-like cells |
| Q36027016 | Reengineering of MeSH thesauri for term selection to optimize literature retrieval and knowledge reconstruction in support of stem cell research |
| Q39630162 | Scalable Production of Cardiomyocytes Derived from c-Myc Free Induced Pluripotent Stem Cells |
| Q35919331 | Small molecules greatly improve conversion of human-induced pluripotent stem cells to the neuronal lineage |
| Q30653613 | Software-aided automatic laser optoporation and transfection of cells |
| Q35796587 | Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches |
| Q31017177 | Stem cell biology and drug discovery. |
| Q42038314 | Stem cells in drug screening for neurodegenerative disease |
| Q30397631 | Technology advancement for integrative stem cell analyses |
| Q38091180 | The 3R principle: advancing clinical application of human pluripotent stem cells |
| Q39813734 | The Janus face of pluripotent stem cells – Connection between pluripotency and tumourigenicity |
| Q37856714 | The use of induced pluripotent stem cells in drug development |
| Q50420577 | Therapeutic effects of stem cells in rodent models of Huntington's disease: Review and electrophysiological findings. |
| Q57341504 | Thermoreversible Hyaluronic Acid-PNIPAAm Hydrogel Systems for 3D Stem Cell Culture |
| Q64965907 | iPSC Technology: Platform for Drug Discovery |
Search more.